News Articles

Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in... INGELHEIM, Germany & INDIANAPOLIS, US -Thursday 30 July 2020  

(BUSINESS WIRE)-- Positive top-line results from the EMPEROR-Reduced Phase III trial in adults with heart failure with reduced ejection fraction, with and without diabetes, were announced today by Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY). EMPEROR-Reduced met its primary...

Boehringer Ingelheim acquires GST to strengthen its stem cell capabilities in Animal Health -Monday 27 July 2020

(BUSINESS WIRE)-- Boehringer Ingelheim, a market leader in animal health, has acquired Global Stem cell Technology (GST), a Belgian veterinary biotech company. GST is dedicated to the research, development and production of evidence-based, regenerative medicines (stem cell therapies) used to...

European Commission approves third nintedanib indication in pulmonary fibrosis1 -Wednesday 15 July 2020  

The approval is for the treatment of adults with other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype beyond idiopathic pulmonary fibrosis (IPF).1 The decision is based on the results of the INBUILD® trial, the first study to evaluate patients with a...

Perceived burden of disease is greater in younger people living with COPD, global survey reveals -Thursday 9 July 2020  

(BUSINESS WIRE) -- Results of a global survey of 1,375 adults aged at least 45 years old and living with Chronic Obstructive Pulmonary Disease (COPD) in 11 countries have been published in COPD: Journal of Chronic Obstructive Pulmonary Disease.1 Findings indicate that COPD has a substantial...

Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Cancer Antibody Pipeline, Expanding Immuno-oncology... -Thursday 14 May 2020  

(BUSINESS WIRE)-- Boehringer Ingelheim today announced the acquisition of Northern Biologics Inc., a wholly owned subsidiary of Northern LP. By acquiring this entity, which focuses on therapeutic antibodies targeting the tumor microenvironment, Boehringer Ingelheim is now positioned at the...

Boehringer Ingelheim Collaborates with CDR-Life to Develop Antibody Fragment-based Therapeutics for Geographic Atrophy,... -Wednesday 13 May 2020

(BUSINESS WIRE) -- Boehringer Ingelheim and CDR-Life today announced they have entered into a collaboration and licensing agreement to research and develop antibody fragment-based therapeutics for geographic atrophy (GA). GA is a progressive, irreversible retinal disease that occurs in patients...

Boehringer Ingelheim’s Aservo® EquiHaler® wins Red Dot for outstanding design... -Tuesday 21 April 2020

(BUSINESS WIRE) -- Boehringer Ingelheim is proud to announce that its Aservo® EquiHaler® received a Red Dot Award for product design. Aservo® EquiHaler® is an inhalant therapy licensed for use in horses with severe equine asthma. The Red Dot Award: Product Design is an international...

European Commission approves nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease... -Tuesday 21 April 2020

(BUSINESS WIRE) -- Boehringer Ingelheim today announced that the European Commission has approved nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) in adults.2 The approval comes after the Committee for Medicinal Products for Human Use had adopted...

COVID-19: Boehringer Ingelheim steps up effort with Global Support Program -Wednesday 8 April 2020

Global support fund for local relief increased to EUR 5.8 million Over 100 scientists and 11,000 lab hours committed to COVID-19 research in international consortia, expected to expand 10 days paid leave offered to 51,000 employees for volunteering EUR 580,000 relief fund made available...

Boehringer Ingelheim receives approval for Aservo® EquiHaler®, industry first therapy for... -Tuesday 4 February 2020

Aservo® EquiHaler® (ciclesonide inhalation solution) is a result of synergies between the company’s human pharma and animal health businesses. The inhaler addresses an unmet need in the equine segment. The company continues to set new standards of care to strengthen its commitment to...

Interim analysis from EMPRISE real-world study shows empagliflozin decreased risk of hospitalisation for heart failure... -Monday 18 November 2019  

(BUSINESS WIRE) -- A new interim analysis of three-year data from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) real-world study on effectiveness shows that empagliflozin was associated with a decreased risk of hospitalisation for heart failure and a similar risk of non-fatal...

Boehringer Ingelheim and Lilly initiate first ever study to assess empagliflozin in people hospitalised for acute heart... -Tuesday 12 November 2019  

(BUSINESS WIRE)-- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced the initiation of EMPULSE, the sixth Phase III study in the empagliflozin heart failure programme. The study will assess whether in-hospital administration of empagliflozin 10 mg daily improves heart...

Results from RE-SPECT CVT® published - first trial of NOAC in cerebral venous thrombosis -Wednesday 4 September 2019  

(BUSINESS WIRE) -- Boehringer Ingelheim today announced the publication of primary analysis from RE-SPECT CVT®, the first exploratory, prospective, randomised controlled study of a NOAC in patients with blood clots in the veins or venous sinuses of the brain. The trial investigated the safety...

Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/glucagon Agonist BI 456906 to Phase 2 Clinical Testing... -Tuesday 3 September 2019  

(BUSINESS WIRE) -- Boehringer Ingelheim and Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL), have announced that Boehringer Ingelheim plans to initiate Phase 2 development of the GLP-1/glucagon dual agonist BI 456906, which was in-licensed from Zealand. Boehringer Ingelheim and Zealand have a...

Boehringer Ingelheim Expands Idiopathic Pulmonary Fibrosis (IPF) Pipeline Through Collaboration and License Agreement... -Thursday 18 July 2019  

(BUSINESS WIRE) -- Boehringer Ingelheim and Bridge Biotherapeutics Inc. today announced that they are entering into a new collaboration and license agreement with the goal of developing Bridge Biotherapeutics’s autotaxin inhibitor BBT-877 for patients with fibrosing interstitial lung...

Boehringer Ingelheim Acquires AMAL Therapeutics, Significantly Enriching Its Cancer Immunology Portfolio with Novel... -Monday 15 July 2019  

(BUSINESS WIRE) -- Boehringer Ingelheim today announced its acquisition of all shares of AMAL Therapeutics SA, a private Swiss biotechnology company focused on cancer immunotherapy and advancing first-in-class therapeutic cancer vaccines derived from its technology platform KISIMA. AMAL’s lead...

Dabigatran’s safety and efficacy established for management of VTE in children -Tuesday 9 July 2019  

(BUSINESS WIRE) -- Boehringer Ingelheim today announced results from two paediatric studies of dabigatran etexilate, which were presented at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress in Melbourne, Australia.1,2 The data showed dabigatran to be as effective...

Boehringer Ingelheim Expands Nonalcoholic Steatohepatitis (NASH) R&D Pipeline With New First-in-Class Compound from... -Monday 1 July 2019  

(BUSINESS WIRE) -- Boehringer Ingelheim and Yuhan Corporation today announced a collaboration and license agreement for the development of a first-in-class dual agonist for the treatment of NASH and related liver diseases that combines GLP-1 and FGF21 activity in one molecule. The collaboration...

Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα... -Tuesday 18 June 2019  

(BUSINESS WIRE) -- Boehringer Ingelheim and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) today announce that the first patient has been dosed in the first-in-human Phase 1 clinical trial evaluating BI 765063, formerly OSE-172, a first-in-class monoclonal antibody antagonist of...

New post-hoc analysis shows consistent cardiorenal risk reductions of empagliflozin in a sub-group of adults with type 2... -Tuesday 11 June 2019  

(BUSINESS WIRE) -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced results of a new post-hoc analysis of data from the EMPA-REG OUTCOME® trial. These results indicated that the effect of empagliflozin on reducing cardiovascular and renal risk was consistent between a...